Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, ...

The company's Q3FY25 consolidated profit plunged 63.6 percent to Rs 3.68 crore versus Rs 10.1 crore, while revenue rose 12.5 ...

As of the latest exchange rate (approximately Rs 83 per USD), $3.1 billion is approximately: Rs 25,730 crore (Rs 25,730,00,00 ...

The company stated that the observations primarily pertain to procedural improvements and are not related to data integrity.

Piramal Pharma's Turbhe facility in Navi Mumbai receives six observations from U.S. FDA inspection, company preparing detailed response.

Let’s delve into the lives of his three esteemed Mukesh Ambani and Nita Ambani's samdhis who are part of India’s richest ...

Piramal Pharma has awarded its integrated media mandate to OMD India, part of Omnicom Media Group. Following a multi-round ...

The Indian pharmaceutical industry has the potential to deliver 100 new drugs for global markets by 2047, driven by enhanced research and development (R&D) efforts, Zydus Lifesciences ...

As part of the mandate, OMD will focus on improving Piramal Pharma’s market presence, brand awareness, consumer engagement, ...

Pankaj R Patel, Chairman of Zydus Lifesciences, envisions India delivering 100 new drugs by 2047, highlighting the importance of research, innovation, and capable human resources. He addressed myths ...

The observations are mainly procedural and do not indicate any data integrity issues, Piramal Pharma added in a regulatory ...

Zydus Lifesciences Chairman Pankaj R Patel predicts that the Indian pharmaceutical industry can develop 100 new drugs by 2047 ...